India Canada city Hyderabad covid-19 information patient India Canada city Hyderabad

CSIR-Laxai receive DCGI nod to begin trials for Colchicine in Covid patients

Reading now: 706
www.livemint.com

CSIR) and Hyderabad-based Laxai Life Sciences will now undertake a two-arm phase-II clinical trial to ascertain safety and efficacy of the drug in improving clinical outcomes during the treatment of Covid-19 patients.

CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu will be the partner institutes in this trial.Back in January, researchers in Canada had first discovered that Colchicine could be used to Covid-19 patients, where is reduced chances of death and hospitalisation by 21 per cent in comparison to placebo.

Colchicine is originally used to treat gout, a complex form of arthritis that occurs when too much uric acid accumulates in joints.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA